Your browser does not support java script. Skip navigation
Loading, please wait  Loading, please wait...
The Rx Consultant 

New Drugs 2013-2014


This CE activity was originally published in The Rx Consultant.  If you received credit for it previously, you cannot receive credit for it again.
 
The FDA approved 27 new molecular entities in 2013, and 9 more through April 15 of 2014. These include 2 selective estrogen receptor modulators for postmenopausal symptoms (ospemifene [Osphena™] and bazedoxifene [in the combination product Duavee®]), the first 2 agents in a new drug class for type 2 diabetes (the SGLT2 inhibitors canagliflozin [Invokana™] and dapagliflozin [Farxiga™]), 2 important drugs for hepatitis C (simeprevir [Olysio™] and sofosbuvir [Sovaldi™]), and a new oral medication for psoriatic arthritis (apremilast [Otezla®]). Recent approvals that are not new molecular entities include a topical gel formulation of brimonidine (Mirvaso®) for rosacea and the reintroduction of doxylamine/pyridoxine (Diclegis®) for nausea and vomiting of pregnancy. This issue focuses on selected noncancer drugs likely to be encountered in outpatient and community practice settings. Selected new anticancer drugs were covered in The Rx Consultant February 2014 issue.
Format
This CE activity is a monograph (PDF file).

Fee

$10.00

CE Hours

2.00

CE Units

0.200

Activity Type

  • Knowledge-based

Target Audience(s)

  • Pharmacists, Nurse Practitioners, Clinical Nurse Specialists, and Registered Nurses

Accreditation(s)

This CE activity was developed by The Rx Consultant, a publication of Continuing Education Network, Inc.

CE activities for Pharmacists and Pharmacy Technicians:
This continuing education (CE) activity meets the requirements of all state boards of pharmacy for approved continuing education hours.  CE credit is automatically reported to CPE Monitor.
 
CE activities for Nurse Practitioners and Clinical Nurse Specialists: 
    This continuing education activity meets the requirements of:
        The American Nurses Credentialing Center (ANCC) for formally approved continuing education (CE) hours, and CE hours of pharmacotherapeutics.
        The American Academy of Nurse Practitioners Certification Program (AANPCP) for acceptable, accredited CE.
 
    This is a pharmacotherapeutics/pharmacology CE activity.
  • The ANCC requires all advanced practice nursing certificants (CNSs and NPs) to complete 25 CE hours of pharmacotherapeutics as a portion of the required 75 continuing education hours.
  • Pharmacology CE is recommended by the AANPCP and will be required for Certificants renewing certification starting January 2017.  
  • Most State Boards of Nursing require a minimum number of pharmacy contact hours to renew an advanced practice license.
 
 
Accreditation Council for Pharmacy Education
Continuing Education Network, Inc. is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

Requirements for CE Credit

To receive CE credit, the participant must read the monograph in its entirety, complete the online post-test and receive a score of 70% or greater, and complete the online evaluation.
 
Pharmacists and Pharmacy Technicians -
 
Be sure your profile has been updated with your NAPB e-profile # and birth date information BEFORE completing the online evaluation, or your credits cannot be reported to CPE Monitor.
 
Continuing pharmacy education credit is automatically reported to CPE Monitor once the post-test & evaluation are successfully completed.

 

 

 

Objectives

  • For each of the drugs reviewed, List the FDA approved indication(s), discuss the evidence supporting the approval, and discuss the potential role(s) in therapy.
  • Describe the significant side effects and drug interactions of each of the drugs reviewed. Provide 2-3 patient counseling tips.
  • For each drug listed in Table 2: List the generic name, brand name, and FDA approved indication(s).

Speaker(s)/Author(s)

James Chan, Pharm.D., PhD


Brief Bio : James Chan, PharmD, PhD, Pharmacy Quality and Outcomes Coordinator, Kaiser Permanente, Oakland, CA and Associate Clinical Professor, School of Pharmacy, University of California, San Francisco, CA.
Disclosure : Dr.Chan reports no financial or personal relationships with any commercial interest producing, marketing, reselling, or distributing a product or service that appears in this issue.

Pamela Mausner, MD


Brief Bio : Pamela Mausner, MD; Medical Writer/Editor and Healthcare Advocate; and Associate Editor, The Rx Consultant.
Disclosure : Dr.Mausner reports no financial relationship with the manufacturer(s) or provider(s) of any commercial product(s) or service(s) that appear in this issue.

Activity Number

0428-0000-14-009-H01-P

Release Date: Jun 18, 2014
Credit Expiration Date: Jun 18, 2017

CE Hours

2.00

Fee

$10.00